ONDINE BIOMEDICAL INC. (OBI) — Investor Presentation of Phase 3 Topline Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the ONDINE BIOMEDICAL INvestor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll, and I'd like to hand you over to the management team. Nicholas, good afternoon, sir. Good afternoon. Thank you so much to everyone at Investor Meet and to 5654 and the help we've received from Angelic Events in our company. Thank you to all participants in this webcast. I'll be talking today about our LANTON Phase three positive top line results and questions there too. I'm going to start by making it clear that this is an investigational product in The US and therefore it's not approved in The US. It is not commercially available for sale in The US. It is limited by federal law to investigational use only. Outside of The United States, we're a commercial for profit company and we sell this product. So I will be referring very carefully within The United States to the results of the Lantern study as being an investigational product. Just a quick primer again on who we are and what the case is for what we're doing. We've developed a brand new approach to disinfection. It's fast, it doesn't produce resistance, it's designed to remove microbes without using antibiotics, which then of course removes the burden of antibiotic resistance development. It is in clinical use today in m...